Sterling Investment Advisors Ltd. boosted its position in United Therapeutics Co. (NASDAQ:UTHR) by 30.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,400 shares of the biotechnology company’s stock after buying an additional 1,250 shares during the period. Sterling Investment Advisors Ltd.’s holdings in United Therapeutics were worth $799,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of UTHR. KBC Group NV raised its stake in shares of United Therapeutics by 3.5% during the 3rd quarter. KBC Group NV now owns 22,974 shares of the biotechnology company’s stock worth $2,692,000 after buying an additional 783 shares during the last quarter. California Public Employees Retirement System raised its stake in shares of United Therapeutics by 1.5% during the 3rd quarter. California Public Employees Retirement System now owns 133,793 shares of the biotechnology company’s stock worth $15,679,000 after buying an additional 1,993 shares during the last quarter. Swiss National Bank raised its stake in United Therapeutics by 1.0% in the 3rd quarter. Swiss National Bank now owns 165,600 shares of the biotechnology company’s stock valued at $19,407,000 after purchasing an additional 1,600 shares during the last quarter. Van ECK Associates Corp raised its stake in United Therapeutics by 9.4% in the 3rd quarter. Van ECK Associates Corp now owns 123,100 shares of the biotechnology company’s stock valued at $14,426,000 after purchasing an additional 10,598 shares during the last quarter. Finally, Wedbush Securities Inc. acquired a new position in United Therapeutics in the 3rd quarter valued at about $435,000.
UTHR has been the subject of several analyst reports. ValuEngine raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 26th. Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price target for the company in a report on Monday, January 15th. HC Wainwright restated a “hold” rating and issued a $95.00 price target on shares of United Therapeutics in a report on Thursday, October 26th. Credit Suisse Group reiterated an “underperform” rating and set a $118.00 target price on shares of United Therapeutics in a report on Thursday, January 18th. Finally, BidaskClub cut United Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 16th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. United Therapeutics presently has an average rating of “Hold” and an average price target of $140.27.
United Therapeutics Co. (NASDAQ:UTHR) opened at $129.50 on Tuesday. United Therapeutics Co. has a 52-week low of $112.01 and a 52-week high of $169.89. The company has a market capitalization of $5,600.00, a P/E ratio of 11.42 and a beta of 1.26.
In related news, CEO Martine A. Rothblatt sold 1,241 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $128.95, for a total transaction of $160,026.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 7,061 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $121.12, for a total value of $855,228.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,136 shares of company stock worth $1,248,989. 7.80% of the stock is currently owned by corporate insiders.
WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/13/sterling-investment-advisors-ltd-buys-1250-shares-of-united-therapeutics-co-uthr.html.
United Therapeutics Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.